Although there have been recent advancements in the understanding of the pathophysiology of glioblastoma multiforme (GBM), as well as modest improvements in its treatment, the overall prognosis for patients with GBM remains poor. While clinical interest in new treatment options to help improve outcomes for these patients is high, the development and incorporation of new technologies and targeted therapies into the treatment paradigm historically has been challenging.
In order to help you increase your understanding of these challenges and provide you with insights into the potential of new technologies—such as Tumor Treating Fields, and novel approaches such as targeted therapies and immunotherapies—to improve patient outcomes, we have developed a dynamic Medical Crossfire® program to share the perspectives of leading clinical experts on the latest data and factors that may change your clinical practice. This exchange of ideas will explore the management of patients with GBM in both the newly diagnosed and recurrent settings, giving you the opportunity to assess the opinions of multidisciplinary experts and optimize your approach to challenging, real-world clinical scenarios.
This education program is directed towards radiation oncologists, researchers, and other oncology healthcare professionals interested in the treatment of GBM.
This activity is supported by an educational grant from Novocure.
Roger Stupp, MD
Chief of Neuro-oncology in the Department of Neurology
Professor of Neurological Surgery, Medicine (Hematology and Oncology) and Neurology (Neuro-oncology)
Feinberg School of Medicine
Erik P. Sulman, MD, PhD
Interim Member of the Faculty, Department of Radiation Oncology
NYU School of Medicine
New York, NY
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High Cancers
Aug 29, 2018
Aug 31, 2018